Online inquiry

IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2756MR)

This product GTTS-WQ2756MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF11 gene. The antibody can be applied in Multiple myeloma (MM), Osteoporosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003701.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8600
UniProt ID O14788
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2756MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10504MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ15983MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ9736MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ6477MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ1518MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ9203MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ15329MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ2478MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW